Latest Content

A study reveals real-world effects of switching to adalimumab biosimilar Hyrimoz, highlighting flare rates and injection pain concerns in inflammatory disease patients.

Speakers at the Institute for Value-Based Medicine event held September 18, 2025, in Nyack, New York, spoke about methods of managing cardio-renal-metabolic disease.

Pirtobrutinib is now fully approved for CLL/SLL in those previously treated with Bruton tyrosine kinase inhibitors.

Connecting primary care providers and commercially insured adults to outpatient behavioral health services via a digital platform improved health outcomes and reduced medical costs.

New research shows that those with dry eye need more than 20 blinks per minute to maintain their tear film.

The authors sought to understand the differential impact of payer-led community-based care management approaches on stakeholder-oriented outcomes for publicly insured adults with multiple chronic conditions.

McKesson's Precision Care Companion initiative enhances biomarker testing and targeted therapies in community oncology, improving patient outcomes and cost efficiency.

With ACA subsidies ending in 2025, Ben Light explains how rising premiums may push individuals toward ICHRAs and reshape employer health coverage strategy.